This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About TRACON Pharmaceuticals Stock (NASDAQ:TCON) Get TRACON Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0550-Day Range$0.02▼$0.0852-Week Range$0.00▼$14.75Volume23,886 shsAverage Volume120,908 shsMarket Capitalization$109.80 thousandP/E Ratio0.01Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Read More Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCON Stock News HeadlinesTRACON Pharma (OTC:TCON) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTRACON Pharmaceuticals Announces it Will Wind Down OperationsJuly 30, 2024 | globenewswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma PatientsJune 11, 2024 | globenewswire.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comTRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comTCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024May 14, 2024 | investorplace.comSee More Headlines TCON Stock Analysis - Frequently Asked Questions How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals's stock reverse split on Wednesday, April 10th 2024.The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META). Company Calendar Last Earnings5/14/2024Today10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCON CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees20Year Founded2006Profitability EPS (Trailing Twelve Months)$3.73 Trailing P/E Ratio0.01 Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.59 million Net MarginsN/A Pretax Margin145.93% Return on Equity-237.65% Return on Assets57.29% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.66 Sales & Book Value Annual Sales$12.05 million Price / Sales0.01 Cash Flow$1.61 per share Price / Cash Flow0.02 Book Value($0.37) per share Price / Book-0.09Miscellaneous Outstanding Shares3,410,000Free Float3,228,000Market Cap$109.80 thousand OptionableNo Data Beta1.37 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TCON) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
